Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19

Abstract

COVID-19 patients exhibit differential disease severity after SARS-CoV-2 infection. It is currently unknown as to the correlation between the magnitude of neutralizing antibody (NAb) responses and the disease severity in COVID-19 patients. In a cohort of 59 recovered patients with disease severity including severe, moderate, mild, and asymptomatic, we observed the positive correlation between serum neutralizing capacity and disease severity, in particular, the highest NAb capacity in sera from the patients with severe disease, while a lack of ability of asymptomatic patients to mount competent NAbs. Furthermore, the compositions of NAb subtypes were also different between recovered patients with severe symptoms and with mild-to-moderate symptoms. These results reveal the tremendous heterogeneity of SARS-CoV-2-specific NAb responses and their correlations to disease severity, highlighting the needs of future vaccination in COVID-19 patients recovered from asymptomatic or mild illness.

Cited by papers we hold 9

• Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms · 2021
  No notice
• Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalised COVID-19 patients · 2021
  Not checked
• Severe Clinical Worsening in COVID-19 and Potential Mechanisms of Immune-Enhanced Disease · 2021
  Not checked
• Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset · 2021
  Not checked
• Evaluation of the genalyte maverick SARS-CoV-2 multi-antigen serology panel · 2021
  Not checked
• Evidence for antibody as a protective correlate for COVID-19 vaccines · 2021
  No notice
• SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay · 2021
  No notice
• S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates · 2021
  No notice
• Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.